Cue Biopharma, Inc.
CUE
$0.84
$0.02182.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.11% | 13.83% | 69.16% | 149.53% | 363.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.11% | 13.83% | 69.16% | 149.53% | 363.98% |
| Cost of Revenue | -18.09% | -16.43% | -12.72% | 10.07% | 15.78% |
| Gross Profit | 22.61% | 22.43% | 24.87% | 5.95% | 2.59% |
| SG&A Expenses | -7.99% | -13.32% | -7.97% | -27.98% | -20.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.38% | -15.58% | -11.49% | -3.25% | 3.37% |
| Operating Income | 18.01% | 19.61% | 20.00% | 14.22% | 8.84% |
| Income Before Tax | 17.17% | 18.78% | 19.83% | 14.03% | 9.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.17% | 18.78% | 19.83% | 14.03% | 9.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.17% | 18.78% | 19.83% | 14.03% | 9.42% |
| EBIT | 18.01% | 19.61% | 20.00% | 14.22% | 8.84% |
| EBITDA | 18.09% | 19.64% | 19.91% | 13.95% | 8.43% |
| EPS Basic | 43.46% | 37.64% | 32.50% | 24.36% | 23.28% |
| Normalized Basic EPS | 43.09% | 37.27% | 32.13% | 24.52% | 23.56% |
| EPS Diluted | 43.46% | 37.64% | 32.50% | 24.36% | 23.28% |
| Normalized Diluted EPS | 43.09% | 37.27% | 32.13% | 24.52% | 23.56% |
| Average Basic Shares Outstanding | 52.79% | 33.05% | 23.01% | 13.19% | 17.79% |
| Average Diluted Shares Outstanding | 52.79% | 33.05% | 23.01% | 13.19% | 17.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |